The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare sector the market is likely to propel to US$1607 Million by 2033.

VVC prevalence has increased due to growing diabetes cases and repeated antibiotic usage among individuals. The market is expected to grow due to an increase in R&D initiatives for precise diagnosis.

The high growth rate can be attributed to the rising disease burden of VVC and increasing testing rates. Positive changes, such as healthcare benefits by the government, increased awareness among consumers, and willingness to avail medical treatments are also expected to drive the growth of the vulvovaginal candidiasis treatment market.

Expand Your Horizons with Free PDF Sample Downloads. Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15875

Rapid increase in the global disease burden, coupled with escalating demand for better treatment options and increasing number of hospital-acquired infections, is also propelling the demand for bacterial vulvovaginal candidiasis treatment.

Furthermore, expanding healthcare infrastructure in developing economies, availability of pharmaceutical drugs, and robust technological advancements in the biopharmaceutical industries are all contributing to significant opportunities for vulvovaginal candidiasis treatment over the forecasted period.

Key Takeaways from the Market Study

  • As of 2023, the vulvovaginal candidiasis treatment market was valued at US$ 1035 Million
  • From 2023 to 2033, the industry is poised to grow at a 4.5% CAGR
  • By 2033, vulvovaginal candidiasis treatment market is slated to reach a valuation of US$ 1607 Million
  • By route of administration, the oral segment accounted for the largest share of 43.2% and is expected to continue this trend over the forecast period.
  • China is poised to yield a CAGR of 4.2% with respect to vulvovaginal candidiasis treatment in 2033

Competitive Landscape

Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc.,Cadila Pharmaceuticals,Bayer AG., Bristol-Myers Squibb Company are some of the key companies in the vulvovaginal candidiasis treatment market.

These players are continuously adopting various strategies such as new product launches, facility expansions, mergers, collaborations, partnerships, and acquisitions to increase their revenue share and gain a competitive edge in the market. for instance,

  • In October 2022 – Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)*.
  • In August 2022 – Mycovia Pharmaceuticals, Inc. announced that it will present VIVJOA™ (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) at the 2022 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. VIVJOA is the first and only FDA-approved medication for RVVC indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential
  • In July 2022 – Mycovia Pharmaceuticals, Inc. announced U.S. availability of VIVJOA™ (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

Key Segments Covered in the Vulvovaginal Candidiasis Treatment Market Industry Survey

Vulvovaginal Candidiasis Treatment Market by Drug Class:

  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others

Vulvovaginal Candidiasis Treatment Market by Route of Administration:

  • Oral Vulvovaginal Candidiasis Treatment
  • Intravenous Vulvovaginal Candidiasis Treatment
  • Topical Vulvovaginal Candidiasis Treatment

Vulvovaginal Candidiasis Treatment Market by Distribution Channel:

  • Hospital Pharmacy for Vulvovaginal Candidiasis Treatment
  • Retail Pharmacy for Vulvovaginal Candidiasis Treatment
  • Online Pharmacy for Vulvovaginal Candidiasis Treatment

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape:

Amniotic Membranes Market: The global amniotic membranes market size is likely to touch a valuation of around US$ 1.4 Bn in 2022. Further, with rising adoption of amniotic membranes for various purposes in ophthalmology, the total sales of amniotic membranes are slated to grow at an impressive CAGR of 9.0% between 2022 and 2028, totalling over US$ 2.3 Bn by the end of 2028.

Digital Radiography Detectors Market: The digital radiography detectors market is valued at US$ 2.13 Bn in 2022. The market is advancing at an average pace with a CAGR of 6.1% through 2026 to reach a valuation of US$ 2.7 Bn. The worldwide market for digital radiography detectors is highly concentrated, with large competitors such as Varex Imaging Corporation and Trixell accounting for about 47% of the market share.

Sepsis Diagnostics Market: The global sepsis diagnostics market is expected to record a CAGR of 8.1% between 2023 and 2033. In 2023, the market is estimated to be valued at US$ 561.2 million. The valuation is expected to cross US$ 1.2 billion by 2033..